Scientific Evidence

Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher

May 2020

TissueCypher provided superior risk stratification that outperformed crypt atypia scores.

Author: Odze R, et al.

Publication: Poster presentation (Sa1203) at DDW 2020, Virtual

Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis

May 2020

An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.

Author: Frei NF, et al.

Publication: Poster presentation (Sa1189) at DDW 2020, Virtual

An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists

Oct 2019

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

Author: Frei NF, et al.

Publication: Poster presentation (372) at ACG 2019, San Antonio

Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus

Oct 2019

TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.

Author: Frei NF, et al.

Publication: Poster presentation (371) at ACG 2019, San Antonio

A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus

Oct 2019

The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.

Author: Hao J, et al.

Publication: ClinicoEconomics and Outcomes Research

An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists

Oct 2019

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

Author: Frei NF, et al.

Publication: Poster presentation (P1990) at UEG 2019, Barcelona

A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus

Oct 2019

The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.

Author: Hao J, et al.

Publication: ClinicoEconomics and Outcomes Research

Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus

Oct 2019

TissueCypher may be an effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.

Author: Frei NF, et al.

Publication: Poster presentation (371) at ACG 2019, San Antonio

An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low grade dysplasia at a rate comparable to expert pathologists

Oct 2019

 

TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.

 

Author: Frei NF, et al.

Publication: Poster presentation (372) at ACG 2019, San Antonio

Independent validation of a tissue systems pathology test to predict progression in Barrett’s esophagus patients

May 2019

TissueCypher identifies NDBE patients who are at increased risk for progression to HGD/EAC and may benefit from increased surveillance or early intervention.

Author: Davison JM, et al.

Publication: Podium presentation (1068) at DDW 2019, San Diego

Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience

Jun 2018

Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.

Author: Diehl DL, et al.

Publication: Poster presentation (Su1109) at DDW 2018, Washington DC

Clinical experience with a multiplexed immunofluorescence tissue biomarker assay (Tissue Cypher BE) in the management of Barrett’s esophagus: a single center experience

Jun 2018

Use of TissueCypher resulted in clinical “upstaging” occurred in 5 of 46 cases, leading to treatment that otherwise might not be pursued.

Author: Diehl DL, et al.

Publication: Poster presentation (Su1109) at DDW 2018, Washington DC